PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Dapagliflozin plus pioglitazone improves glycemia and hepatic steatosis markers

dapagliflozinpioglitazoneSGLT2 inhibitorthiazolidinedionetype 2 diabetesMASLDNAFLDNASHcombination therapymeta-analysishepatic steatosisglycemic control Endocrinology / Diabetes / Obesity

Background Information

Improved glycemic and liver outcomes found with combination therapy in T2DM.

This meta-analysis evaluates the effectiveness of dapagliflozin plus pioglitazone in adults with type 2 diabetes mellitus (T2DM), providing insights into metabolic and hepatic outcomes. The combination therapy improved glycemic control by reducing hemoglobin A1c (HbA1c) by -0.49% and showed positive effects on liver fat and steatosis markers. While the findings indicate potential benefits for patients with T2DM and metabolic dysfunction-associated steatotic liver disease (MASLD), caution is advised due to moderate to low certainty evidence and reliance on surrogate endpoints. Dapagliflozin and pioglitazone combination improves glycemic and hepatic outcomes in T2DM with moderate evidence.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Joshi S, Samajdar SS, Gupta A, Bhartia M, Lodha S, Bhattacharyya S, Seshadri K, Nagendra L, Unnikrishnan AG, Padhye D, Kopalle LN, Das AK, Lakhani O, Kesavadev J, Joshi A, Das S, Gadia S, Anthuvan T

Citation: Joshi S, Samajdar SS, Gupta A, et al. Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study. Frontiers in clinical diabetes and healthcare. 2026;7:1733995. doi:10.3389/fcdhc.2026.1733995

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.